Fasentin’s mechanism is well understood in the inhibition of GLUT1, however, its role in suppressing tumor growth has been vaguely discussed [40], but not yet within the context of diffuse gliomas, and certainly not in GBM. Here, SLC2A1 is linked to neoplasm.